Fig. 5

Mutual regulation of PVT1 and YAP1 in EAC cells. a. Reverse-phase protein arrays (RPPA) revealed changes in total YAP1 (left) and phosphorylated YAP1 (Ser 127) (right) treated with or without PVT1 ASOs. *p < 0.05. b. Correlation analysis (Pearson’s correlation) between PVT1 and YAP1 expression in 103 EAC patients. Pearson’s correlation (scatter plot) of expression levels between PVT1 and YAP1 in patients with EAC (r = 0.6319, p < 0.0001). c. Total YAP1 level and phosphor-YAP1 (Ser 127) or phosphor-LATS1(Ser 909) were determined by Western blot in OE19 and JHESO cell lines treated with PVT1 ASO at concentration indicated. d. Immunofluorescent staining of YAP1 and phosphor-LATS1 in OE19 and JHESO cell lines treated with PVT1 ASO. Scale bar; 25 μm. e. Level of YAP1 and its targets-SOX9 and CTGF as well as PVT1 level were determined by Western blot and qPCR in SKGT-4 cells with or without YAP1 induction (Doxycycline; DOX+)., f. YAP1 and PVT1 level was detected by q-PCR or western blot in YAP1 knockout clones (YAP1 KO1 and YAP1 KO2) with LentiCRISPR/Cas9 compared to control cells. PVT1 expression was dramatically decreased (bottom) upon knock out YAP1 in SKGT-4 EAC cells. Error bars, mean ± SEM. ** P < 0.01